pathophysiological interactions and their therapeutic consequences are reviewed regarding 21-hydroxylase deficiency congenital adrenal hyperplasia , ovary and adrenal virilizing tumours , addison disease , primary hyperaldosteronism , pheochromocytoma , graves ' disease , hashimoto thyroiditis , primary hypothyroidism , primary hypo- and hyperparathyroidism and bromocriptine treatment of hyperprolactinaemia .
C0006230
bromocriptine
C0020514
hyperprolactinaemia